Clinical Trials and Research

Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively. One common type…

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart…

The US Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug (PRX004) for the treatment of transthyretin-mediated amyloid…

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduces serum transthyretin variability and…

Light chain (AL) amyloidosis is caused by misfolded light chains depositing in tissues in the form of fibrils, leading to organ damage  [1]. Treatment consists…

1 IntroductionSystemic light chain amyloidosis (AL) occurs due to a clonal plasma cell dyscrasia, typically with multi-system involvement and associated with a poor…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults.…

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM,…

Bayer has announced successful results from a Phase III clinical trial evaluating its investigational PET tracer, iodine 124 evuzamitide, designed for diagnosing…

This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s (LSE: AZN) Phase III CARDIO-…